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We report the ﬁrst case of spontaneous chylothorax complicating small cell lung cancer. A 52 year old
female presented with exertional dyspnoea, left-sided chest and neck pain, and dysphagia. The chest X-
ray on admission revealed a large left-sided pleural effusion. A subsequent CT chest showed a large
anterior mediastinal mass with a left brachiocephalic and jugular vein thrombosis. The patient under-
went medical thoracoscopy with chest drain insertion, which drained pleural ﬂuid high in triglycerides,
consistent with a chylothorax. Due to its uncommon nature, the management of chylothorax is not well
deﬁned. Alongside the case report, we provide a review of aetiology, mechanism and diagnosis with a
brief summary of treatment options.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
A chylothorax is a rare condition in which damage or obstruc-
tion to the thoracic duct results in chyle leakage into the pleural
space, often right-sided. Chyle is composed of lymph (of which
immunoglobulins and T-lymphocytes are the main constituents)
and fats absorbed from the digestive tract. Chylothorax can occur
secondary to damage or obstruction of the thoracic duct and its
tributaries. Common causes include trauma and malignancy. The
incidence of spontaneous chylothorax associated with primary
lung cancer is rare.. No Acid Fast Bacilli
blood mixed
ol/L
mol/L
ffusion. No malignant cells
hs.uk (A. Kavidasan).
Ltd. This is an open access article uDyspnoea, chest pain and tachycardia are common pre-
sentations [1]. Pleuritic pain and fever, however, are not features as
chyle is not irritant to the pleura. Deﬁnitive diagnosis requires
pleural ﬂuid analysis to measure the proportions of different lipids.
We present here a case of left-sided chylothorax in a patient un-
dergoing chemotherapy for a primary small cell lung cancer.Case presentation
A 52 year old non-smoker female, solicitor by profession, pre-
sented with worsening breathlessness and pain (intensity 7/10) on
the left side of the neck, chest and left scapular region sometimes
radiating to the head causing headaches. She also described
dysphagia for ﬂuids but not solids and worsening breathlessness
on exertion. Initial observations were in normal limits. There was
reduced air entry in the left lung base. Bloods were unremarkable
except for a raised CRP of 36 (normal range 0e6). Chest x-ray
showed a large left pleural effusion (Fig. 1). A CT chest conﬁrmed an
irregular mass in the superior mediastinum associated with left
brachiocephalic and jugular vein thrombosis (Fig. 2). The patient
underwent local anaesthetic medical thoracoscopy, drainage of
pleural ﬂuid and intercostal chest drain insertion. 1300 ml of or-
ange coloured ﬂuid was drained (Fig. 3). Biochemical analysis
identiﬁed high levels of triglycerides, suggesting a chylothorax.
Subsequent CT guided biopsy and histological analysis showed
features consistent with small cell lung cancer (Supplementarynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. CXR: Left-sided pleural effusion. Mediastinal mass.
Fig. 3. Medical thoracoscopy.
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and carboplatin and etoposide but continued to deteriorate and
passed away.Discussion: aetiology, mechanism, discussion & differential
diagnosis
Aetiology
Chylothorax represents 2% of all pleural effusions [2]. Trauma,
both iatrogenic and non-iatrogenic, is the main cause of chylo-
thorax. Of iatrogenic trauma, thoracic surgery is a common pre-
cipitant with esophagectomy being a frequent offender (3% of
operations) [3]. Non-iatrogenic causes include penetrating trauma,
fractures and childbirth [4]. Of non-traumatic cases, 70% are due to
lymphoma [4]. Other reported associations are sarcoidosis,
amyloidosis, congenital duct abnormalities, SVC thrombosis and
yellow nail syndrome.Fig. 2. CTPA: Large mediastinal/left upper lobe mass. Left jugular vein compressed by
upper margin of masses. Appearances suspicious for left brachiocephalic and jugular
vein thrombosis.Mechanism
The mechanism of chyle formation involves damage to the
thoracic duct, which is the main conduit for lymphatic drainage, or
obstruction of lymphatic tributaries, leading to extravasation of
chyle [5]. Leakage leads to formation of a chyloma, which can pre-
sent as a supraclavicular swelling. Eventually the pleura ruptures
and chyle accumulates forming a chylothorax, usually on the right
side. There is large variation in the anatomy of the lymphatic system,
likely due to embryological bilateral thoracic ducts [5]. In 65% of the
population [4], the thoracic duct starts from the level of the second
lumbar vertebra, travels alongside the aorta, and ascends to the neck
to drain into the left subclavian vein [4,5]. Ducts within the system
and the pressure changes from breathing help maintain the ﬂow of
chyle. Fats absorbed from the digestive tract and lymph from the
lower half of the body combine to form chyle. 2e4 L/day of chyle is
transported via the thoracic duct [3], thus large collections can
quickly form if the system is damaged or obstructed.
Discussion
Our patient's presentation of a chylothorax complicating small
cell lung cancer is likely secondary to jugular vein thrombosis and
compression from the anterior mediastinal mass. In cases lacking a
signiﬁcant background, chylothorax should raise the suspicion of
malignancy and patients should be investigated for this. In patients
with associated trauma, the common approach is pleural ﬂuid
analysis along with assessment for a leakage site with CT or
lymphangiography [4]. Further interventions depend upon the
cause, with medical and surgical options available. Our patient was
managed with therapeutic thoracocentesis. She then went on to
have radiotherapy for the lung cancer. Consideration should be
given to consequences of chylothorax. Depletion of chyle results in
loss of fats, fat-soluble vitamins, protein and therefore weight loss
and malnutrition. Loss of immunoglobulins and T-lymphocytes can
impair the immune system in severe cases. Chyle itself is bacte-
riostatic so the risk from infection here is low. However, there is
50% mortality in untreated chylothorax from the associated com-
plications [3]. Initial management of these patients should include
aggressive treatment to correct hypovolaemia, electrolyte imbal-
ances and immunosuppression.
Differential diagnosis
Chylothorax, pseudochylothorax and empyema can be distin-
guished by the following criteria. Firstly, by physical appearance:
the classical appearance of a chylothorax is of a milky, opalescent
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if the patient has been fasting this may be clear, and in traumatic
cases it may be bloody [3]. Secondly, by biochemical criteria: a
triglyceride level >110 mg/dL, cholesterol level <200 mg/dL 50% of
cases [3] are exudative i.e. high protein and low lactate dehydro-
genase. If the effusion is transudative this may indicate an under-
lying hepatic or cardiac cause, for example, cirrhosis [5]. Lastly, by
ﬂuid analysis, which is the deﬁnitive test. Presence of chylomicrons,
small particles made up of long chains of triglycerides, is diagnostic
as these are absorbed directly into and transported by the
lymphatic system. These lipids can be detected with Sudan staining
but this technique should be supported with ﬂuid analysis as it has
a low speciﬁcity [4]. Currently there are no quantitative criteria for
diagnosis. If chylomicron testing is not available, triglycerides
quantiﬁcation can be used to aid identiﬁcation. A pseudochylo-
thorax is an effusion that may appear similar to chylothorax but
does not fulﬁl the biochemical criteria. It is the result of a chronic
effusion that may develop over months to years, which can be
distinguished by its high cholesterol content. The deﬁning criteria
is a cholesterol >200 mg/dL with triglyceride <50 mg/dL but it can
be > 1000 mg/dL [5]. The origin of the cholesterol is thought to be
through the continued breakdown of inﬂammatory cells in a
chronic effusion. 54% are caused by tuberculous effusions [5]. Other
causes include rheumatoid pleurisy, trapped lung syndrome and
partially drained empyemas. The milky appearance of pseudochyle
will also disappear on addition of ethyl ether-another method of
distinguishing from chyle [4]. In addition to clinical history and
examination, chylothorax can be differentiated from empyema
with centrifugation. Chyle will remain uniform after being pro-
cessed whereas empyema will form a supernatant [4].
Conclusion
The circumstances of this patient's case are of interest as the
background upon which her chylothorax developed is rare. It
highlights the issues to consider in diagnosis and initial manage-
ment. Currently there is not enough evidence to suggest the
optimal management of these patients but the general consensus isto manage nutrition aggressively and to, where possible, manage
conservatively unless surgical intervention is indicated. Ultimately,
the treatment of a chylothorax in such circumstances should be
directed to treat the primary tumour. It is important to consider a
chylothorax early when faced with a pleural effusion in order to
avoid complications such as hypotension, malnutrition and
immunosuppression.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.rmcr.2015.02.005.References
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